Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932007 | 0.87 | BRAF (0.38) | BRAFLCKKDR | |
| SCHEMBL9932669 | 0.83 | BRAF (0.43) | BRAF | |
| SCHEMBL9967956 | 0.80 | BRAF (0.66) | BRAF | |
| SCHEMBL9932549 | 0.77 | BRAF (0.41) | BRAFKDR | |
| SCHEMBL11971843 | 0.73 | BRAF (0.48) | BRAFLCKSMN1; SMN2FGFR4 | |
| SCHEMBL9932667 | 0.70 | JAK1 (0.40) | BRAF | |
| SCHEMBL8293816 | 0.68 | BRAF (0.48) | BRAFLCKFGFR4 | |
| SCHEMBL2623135 | 0.68 | KDM4E (0.39) | SMN1; SMN2 | |
| SCHEMBL17372625 | 0.67 | TARS1 (0.31) | — | |
| SCHEMBL17372629 | 0.67 | TARS1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885LCK 329/4885KDR 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.